Lenalidomide Use in Myelodysplastic Syndromes: Insights Into the Biologic Mechanisms and Clinical Applications

Cancer - United States
doi 10.1002/cncr.30585
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Practical Considerations in the Use of Lenalidomide Therapy for Myelodysplastic Syndromes

Cancer Control
MedicineOncologyHematology
2006English

Lenalidomide: Targeted Anemia Therapy for Myelodysplastic Syndromes

Cancer Control
MedicineOncologyHematology
2006English

Impact of Lenalidomide Use Among Non-Transfusion Dependent Patients With Myelodysplastic Syndromes

American Journal of Hematology
Hematology
2018English

A Calcium- And Calpain-Dependent Pathway Determines the Response to Lenalidomide in Myelodysplastic Syndromes

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2016English

Management of Cytopenias During Treatment With Lenalidomide in Patients With Myelodysplastic Syndromes

The Open Leukemia Journal
2010English

ABC of Clinical Haematology: The Myelodysplastic Syndromes

BMJ
1997English

Cost Effectiveness of Lenalidomide in the Treatment of Transfusion-Dependent Myelodysplastic Syndromes in the United States

Cancer Control
MedicineOncologyHematology
2006English

The Myelodysplastic Syndromes

Emerging Cancer Therapeutics
2011English

The Myelodysplastic Syndromes

Oncologist
Cancer ResearchMedicineOncology
1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy